Drug profile · INN
lomitapide mesylate
JUXTAPID
lomitapide mesylate (JUXTAPID) is a microsomal triglyceride transfer protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — lomitapide mesylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
lomitapide mesylate (JUXTAPID) is a microsomal triglyceride transfer protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Microsomal triglyceride transfer protein inhibitor
Primary target: Microsomal triglyceride transfer protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Frequently asked questions
What is lomitapide mesylate?
lomitapide mesylate (JUXTAPID) is a microsomal triglyceride transfer protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lomitapide mesylate?
JUXTAPID is a marketed brand name for lomitapide mesylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lomitapide mesylate?
lomitapide mesylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.